Home | Business News | Browse by Publication | B | Biotech Business

ALEXION'S SOLIRIS PREVENTS REJECTION IN KIDNEY TRANSPLANTS.

Publication: Biotech Business
Publication Date: 01-JUL-09 		Format: Online
Delivery: Immediate Online Access
Full Article Title: ALEXION'S SOLIRIS PREVENTS REJECTION IN KIDNEY TRANSPLANTS.(Clinical report)

Article Excerpt
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has announced that researchers presented early clinical and laboratory data on the potential role of terminal complement inhibition with Soliris(r) (eculizumab) for the treatment of a subset of kidney transplant patients who are at high risk for antibody-mediated rejection (AMR) of their grafts. These data were included in three oral sessions and one poster presentation at the American Transplant Congress held in Boston. This research includes interim results from an investigator-initiated study of Soliris(r) for the prevention...

Access Full Article, Compliments of Goliath

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.